APAC Fat Reduction Market - Industry Trends and Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION 211

• 1.1 OBJECTIVES OF THE STUDY 211
• 1.2 MARKET DEFINITION 211
• 1.3 OVERVIEW OF THE ASIA PACIFIC FAT REDUCTION MARKET 211
• 1.4 CURRENCY AND PRICING 213
• 1.5 LIMITATIONS 213
• 1.6 MARKETS COVERED 214

2 MARKET SEGMENTATION 219

• 2.1 MARKETS COVERED 219
• 2.2 GEOGRAPHICAL SCOPE 220
• 2.3 YEARS CONSIDERED FOR THE STUDY 221
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 222
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 225
• 2.6 MULTIVARIATE MODELLING 226
• 2.7 TYPE LIFELINE CURVE 226
• 2.8 DBMR MARKET POSITION GRID 227
• 2.9 VENDOR SHARE ANALYSIS 228
• 2.10 MARKET APPLICATION COVERAGE GRID 229
• 2.11 SECONDARY SOURCES 230
• 2.12 ASSUMPTIONS 230

3 EXECUTIVE SUMMARY 231

4 PREMIUM INSIGHT 235

• 4.1 PESTEL ANALYSIS 237
• 4.2 PORTER'S FIVE FORCES 238
• 4.3 MARKET ANALYSIS 239
• 4.4 ASIA PACIFIC (PRICING AND PROCEDURE ANALYSIS) 240
  • 4.4.1 JAPAN 240
  • 4.4.2 INDIA 241
  • 4.4.3 CHINA 242
  • 4.4.4 SOUTH KOREA 243
  • 4.4.5 THAILAND 244
  • 4.4.6 MALAYSIA 245
  • 4.4.7 SINGAPORE 246
  • 4.4.8 AUSTRALIA 247
  • 4.4.9 PHILIPPINES 248
  • 4.4.10 TAIWAN 249
  • 4.4.11 INDONESIA 250
  • 4.4.12 NEW ZEALAND 251
  • 4.4.13 VIETNAM 252
  • 4.4.14 PAKISTAN 253
  • 4.4.15 UZBEKISTAN 254
  • 4.4.16 MYANMAR 255
  • 4.4.17 NEPAL 256
  • 4.4.18 COMBODIA 257
• 4.5 BRAND ANALYSIS 258
  • 4.5.1 KYBELLA 258
  • 4.5.2 AQUALYX 259
• 4.6 PRICING ANALYSIS (USD) 260
  • 4.6.1 ASIA-PACIFIC 260
    • 4.6.1.1 JAPAN 260
    • 4.6.1.2 INDIA 260
    • 4.6.1.3 CHINA 260
    • 4.6.1.4 SOUTH KOREA 261
    • 4.6.1.5 THAILAND 261
    • 4.6.1.6 MALAYSIA 261
    • 4.6.1.7 SINGAPORE 262
    • 4.6.1.8 AUSTRALIA 262
    • 4.6.1.9 PHILIPPINES 262
    • 4.6.1.10 TAIWAN 263
    • 4.6.1.11 INDONESIA 263
    • 4.6.1.12 NEW ZEALAND 263
    • 4.6.1.13 VIETNAM 264
    • 4.6.1.14 PAKISTAN 264
    • 4.6.1.15 UZBEKISTAN 264
    • 4.6.1.16 MYANMAR 265
    • 4.6.1.17 NEPAL 265
    • 4.6.1.18 COMBODIA 265
• 4.7 PATENT ANALYSIS OF THE ASIA PACIFIC FAT REDUCTION MARKET 266
  • 4.7.1 JAPAN 266
    • 4.7.1.1 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 266
    • 4.7.1.2 METHOD FOR TREATING ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND ITS SALTS 267
    • 4.7.1.3 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 267
    • 4.7.1.4 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 268
  • 4.7.2 AUSTRALIA 268
    • 4.7.2.1 TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF 268
    • 4.7.2.2 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 269
  • 4.7.3 CHINA 270
    • 4.7.3.1 THE PREPARATION OF DEOXYCHOLIC ACID AND ITS SALT 270
    • 4.7.3.2 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 270
    • 4.7.3.3 TREATMENT USING DEOXYCHOLIC ACID AND ITS SALT TO THE FAT OF ACCUMULATION 271
  • 4.7.4 INDIA 272
  • 4.7.5 SOUTH KOREA 272
• 4.8 PRICING ANALYSIS (USD) 273
  • 4.8.1 KYBELLA 273
  • 4.8.2 COOLSCULPTING 275
  • 4.8.3 COOLSCULPTING ELITE 277
  • 4.8.4 COOLTONE 279

5 INDUSTRY INSIGHTS: 282

• 5.1 DEMOGRAPHIC TRENDS: 283
• 5.2 CONCLUSION: 284

6 ASIA PACIFIC FAT REDUCTION MARKET, REGULATIONS 285

• 6.1 JAPAN 285
  • 6.1.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 285
  • 6.1.2 REGULATORY APPROVAL AGENCIES 285
  • 6.1.3 REVIEW, CATEGORIZE, AND PERFORM INGREDIENT ANALYSIS FOR THE AESTHETIC PRODUCT. 285
  • 6.1.4 OBTAINING REQUIRED LICENSES. 286
  • 6.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 286
  • 6.1.6 COSMETIC & QUASI-DRUG MARKETING NOTIFICATION SUBMISSION. 286
  • 6.1.7 IMPORT THE COSMETICS AND QUASI DRUGS INTO JAPAN. 286
  • 6.1.8 PRIMARY DISTRIBUTION APPROVAL 286
  • 6.1.9 COSMETIC MANUFACTURING LICENSE (PACKAGING, LABELING, AND STORAGE). 286
• 6.2 CHINA 287
  • 6.2.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 287
  • 6.2.2 LICENSING AND REGISTRATION 287
  • 6.2.3 REGULATORY APPROVAL AGENCIES 288
  • 6.2.4 POST-MARKETING SURVEILLANCE 288
• 6.3 SOUTH KOREA 288
  • 6.3.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 288
  • 6.3.2 REGULATORY APPROVAL AGENCIES 289
  • 6.3.3 LICENSING AND REGISTRATION 289
  • 6.3.4 POST-MARKETING SURVEILLANCE 289
  • 6.3.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 289
• 6.4 INDIA 289
  • 6.4.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 289
  • 6.4.2 LICENSING AND REGISTRATION 290
  • 6.4.3 REGULATORY APPROVAL AGENCIES 291
  • 6.4.4 POST-MARKETING SURVEILLANCE 291
• 6.5 AUSTRALIA 291
  • 6.5.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 291
  • 6.5.2 REGULATORY APPROVAL AGENCIES 292
  • 6.5.3 LICENSING AND REGISTRATION 292
  • 6.5.4 POST-MARKETING SURVEILLANCE 292
  • 6.5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 292
• 6.6 SINGAPORE 292
  • 6.6.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 292
  • 6.6.2 REGULATORY APPROVAL AGENCIES 292
  • 6.6.3 LICENSING AND REGISTRATION 293
  • 6.6.4 POST-MARKETING SURVEILLANCE 293
  • 6.6.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 293
• 6.7 THAILAND 293
  • 6.7.1 THAILAND DRUG REGISTRATION 293
  • 6.7.2 GENERIC DRUG 293
• 6.8 MALAYSIA 295
  • 6.8.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 295
  • 6.8.2 REGULATORY APPROVAL AGENCIES 295
  • 6.8.3 LICENSING AND REGISTRATION 295
  • 6.8.4 POST-MARKETING SURVEILLANCE 295
• 6.9 INDONESIA 296
  • 6.9.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 296
  • 6.9.2 REGULATORY APPROVAL AGENCIES 296
  • 6.9.3 LICENSING AND REGISTRATION 296
• 6.10 PHILIPPINES 296
  • 6.10.1 GET A LICENSE TO OPERATE FROM THE FDA IN THE PHILIPPINES: 297
• 6.11 NEW ZEALAND 298
  • 6.11.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 298
  • 6.11.2 TIMELINE 298
  • 6.11.3 REGULATORY APPROVAL AGENCIES 298
  • 6.11.4 LICENSING AND REGISTRATION 299
  • 6.11.5 GOOD CLINICAL PRACTICE REQUIREMENTS 299
• 6.12 TAIWAN 299
  • 6.12.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 299
  • 6.12.2 TIMELINE: 300
  • 6.12.3 REGULATORY APPROVAL AGENCIES 300
  • 6.12.4 POST MARKETING SURVEILLANCE 300
• 6.13 CAMBODIA 300
  • 6.13.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 300
  • 6.13.2 REGULATORY APPROVAL AGENCIES 302
  • 6.13.3 LICENSING AND REGISTRATION 302
  • 6.13.4 POST-MARKETING SURVEILLANCE 302
• 6.14 NEPAL 303
  • 6.14.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 303
  • 6.14.2 REGULATORY APPROVAL AGENCIES 303
• 6.15 PAKISTAN 303
  • 6.15.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 303
  • 6.15.2 REGULATORY APPROVAL AGENCIES 303
  • 6.15.3 LICENSING AND REGISTRATION 303
• 6.16 UZBEKISTAN 304
  • 6.16.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 304
  • 6.16.2 REGULATORY APPROVAL AGENCIES 304
  • 6.16.3 LICENSING AND REGISTRATION 304
• 6.17 VIETNAM 304
  • 6.17.1 REGULATORY APPROVAL TIMELINE 304
  • 6.17.2 REGULATORY APPROVAL AGENCIES 304
  • 6.17.3 LICENSING AND REGISTRATION 304

7 PIPELINE ANALYSIS OF THE ASIA PACIFIC FAT REDUCTION MARKET 305

8 MARKET ACCESS 312

• 8.1 MANUFACTURER AND STRATEGIC DEALS 312
• 8.2 CURRENT TREATMENT PRACTICES 312
• 8.3 IMPACT OF UPCOMING THERAPY 313

9 MARKET OVERVIEW 314

• 9.1 DRIVERS 316
  • 9.1.1 INCREASING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 316
  • 9.1.2 GROWING AESTHETIC CONSCIOUSNESS AND BEAUTY STANDARDS 317
  • 9.1.3 GROWING TECHNOLOGICAL ADVANCEMENTS 318
  • 9.1.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 319
• 9.2 RESTRAINTS 320
  • 9.2.1 HIGH COST OF PROCEDURES 320
  • 9.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 321
  • 9.2.3 PRODUCT RECALL 321
• 9.3 OPPORTUNITIES 322
  • 9.3.1 CUSTOMIZED TREATMENT PLANS AND INTEGRATION WITH OTHER AESTHETIC PROCEDURES 322
  • 9.3.2 BELIEF AND TREND OF FAT REDUCTION IN YOUNG ADULTS 323
  • 9.3.3 FOCUS ON INCLUSIVITY AND DIVERSITY AND EXPANSION OF PRODUCT LINES 325
• 9.4 CHALLENGES 327
  • 9.4.1 LONG-TERM EFFICACY AND SUSTAINABILITY 327
  • 9.4.2 LONGER RECOVERY TIME OF THE PROCEDURE 327

10 ASIA PACIFIC FAT REDUCTION MARKET, BY TYPE 329

• 10.1 OVERVIEW 330
• 10.2 SURGICAL FAT REDUCTION 333
  • 10.2.1 LIPOSUCTION 334
    • 10.2.1.1 BY TYPE 335
      • 10.2.1.1.1 ULTRASOUND-ASSISTED LIPOSUCTION 335
      • 10.2.1.1.2 LASER-ASSISTED LIPOSUCTION 336
      • 10.2.1.1.3 TUMESCENT LIPOSUCTION 336
      • 10.2.1.1.4 SUPER-WET TECHNIQUE 336
    • 10.2.1.2 BY APPLICATION 336
      • 10.2.1.2.1 ABDOMINAL FAT 337
      • 10.2.1.2.2 THIGHS FAT 337
      • 10.2.1.2.3 BUTTOCK FAT 337
      • 10.2.1.2.4 UPPER-ARM FAT 337
      • 10.2.1.2.5 FACIAL FAT-DEPOSITS 337
      • 10.2.1.2.5.1 SUBMENTAL AREAS 338
      • 10.2.1.2.5.2 MALAR 338
      • 10.2.1.2.5.3 MANDIBULAR 338
      • 10.2.1.2.6 KNEE FAT 338
  • 10.2.2 SURGICAL REJUVENATION 338
    • 10.2.2.1 FACE LIFT 339
    • 10.2.2.2 NECK LIFT 339
  • 10.2.3 CHIN IMPLANT 339
    • 10.2.3.1 SILICONE CHIN IMPLANTS 340
    • 10.2.3.2 OTHERS 340
  • 10.2.4 PORUS IMPLANTS 340
    • 10.2.4.1 TEFLON 341
    • 10.2.4.2 GORE-TEX 341
    • 10.2.4.3 MEDPORE IMPLANTS 341
• 10.3 NON-INVASIVE FAT REDUCTION 341
  • 10.3.1 CRYOLIPOLYSIS 344
    • 10.3.1.1 COOL SCULPTING 344
    • 10.3.1.2 COOL SCULPTING ELITE 344
    • 10.3.1.3 COOL TONE 345
    • 10.3.1.4 OTHERS 345
      • 10.3.1.4.1 ABDOMINAL FAT 345
      • 10.3.1.4.2 THIGHS FAT 345
      • 10.3.1.4.3 BUTTOCK FAT 346
      • 10.3.1.4.4 UPPER-ARM FAT 346
      • 10.3.1.4.5 FACIAL FAT-DEPOSITS 346
      • 10.3.1.4.6 KNEE FAT 346
  • 10.3.2 ULTRASOUND 346
    • 10.3.2.1 INTERNAL ULTRASONIC LIPOSUCTION 347
    • 10.3.2.2 EXTERNAL ULTRASONIC LIPOSUCTION 347
      • 10.3.2.2.1 ABDOMINAL FAT 348
      • 10.3.2.2.2 THIGHS FAT 348
      • 10.3.2.2.3 BUTTOCK FAT 348
      • 10.3.2.2.4 UPPER-ARM FAT 348
      • 10.3.2.2.5 FACIAL FAT-DEPOSITS 348
      • 10.3.2.2.6 KNEE FAT 348
  • 10.3.3 RADIOFREQUENCY 349
    • 10.3.3.1 ABDOMINAL FAT 349
    • 10.3.3.2 THIGHS FAT 349
    • 10.3.3.3 BUTTOCK FAT 349
    • 10.3.3.4 UPPER-ARM FAT 349
    • 10.3.3.5 FACIAL FAT-DEPOSITS 350
    • 10.3.3.6 KNEE FAT 350

• 10.3.4 LOW LEVEL LASER THERAPY 350
  • 10.3.4.1 ABDOMINAL FAT 350
  • 10.3.4.2 THIGHS FAT 350
  • 10.3.4.3 BUTTOCK FAT 351
  • 10.3.4.4 UPPER-ARM FAT 351
  • 10.3.4.5 FACIAL FAT-DEPOSITS 351
  • 10.3.4.6 KNEE FAT 351
• 10.3.5 OTHERS 351
• 10.4 MINIMALLY INVASIVE 351
  • 10.4.1 INJECTION LIPOLYSIS 353
    • 10.4.1.1 DEOXYCHOLIC ACID INJECTIONS 353
      • 10.4.1.1.1 KYBELLA/BELKYRA 354
      • 10.4.1.1.1.1 FACIAL FAT-DEPOSITS 355
      • 10.4.1.1.1.2 UPPER-ARM FAT 355
      • 10.4.1.1.1.3 ABDOMINAL FAT 355
      • 10.4.1.1.1.4 THIGHS FAT 355
      • 10.4.1.1.1.5 KNEE FAT 355
      • 10.4.1.1.1.6 BUTTOCK FAT 355
      • 10.4.1.1.2 AQUALYX 356
      • 10.4.1.1.2.1 FACIAL FAT-DEPOSITS 356
      • 10.4.1.1.2.2 UPPER-ARM FAT 356
      • 10.4.1.1.2.3 ABDOMINAL FAT 356
      • 10.4.1.1.2.4 THIGHS FAT 357
      • 10.4.1.1.2.5 KNEE FAT 357
      • 10.4.1.1.2.6 BUTTOCK FAT 357
    • 10.4.1.2 PHOSPHATIDYLCHOLINE 357
      • 10.4.1.2.1 FACIAL FAT-DEPOSITS 358
      • 10.4.1.2.2 UPPER-ARM FAT 358
      • 10.4.1.2.3 ABDOMINAL FAT 358
      • 10.4.1.2.4 THIGHS FAT 358
      • 10.4.1.2.5 KNEE FAT 358
      • 10.4.1.2.6 BUTTOCK FAT 358
    • 10.4.1.3 OTHERS 358
  • 10.4.2 OTHERS 358

11 ASIA PACIFIC FAT REDUCTION MARKET, BY APPLICATION 359

• 11.1 OVERVIEW 360
• 11.2 ABDOMINAL FAT 363
• 11.3 THIGHS FAT 364
• 11.4 BUTTOCK FAT 365
• 11.5 UPPER-ARM FAT 366
• 11.6 FACIAL FAT-DEPOSITS 367
  • 11.6.1 SUBMENTAL AREAS 368
  • 11.6.2 MANDIBULAR 368
  • 11.6.3 MALAR 368
• 11.7 KNEE FAT 368

12 ASIA PACIFIC FAT REDUCTION MARKET, BY GENDER 370

• 12.1 OVERVIEW 371
• 12.2 FEMALE 374
• 12.3 MALE 375

13 ASIA PACIFIC FAT REDUCTION MARKET, BY AGE GROUP 376

• 13.1 OVERVIEW 377
• 13.2 ADULT 380
• 13.3 GERIATRIC 381
• 13.4 CHILD 382

14 ASIA PACIFIC FAT REDUCTION MARKET, BY END USER 384

• 14.1 OVERVIEW 385
• 14.2 HOSPITALS 388
  • 14.2.1 BY TYPE 389
    • 14.2.1.1 PRIVATE 389
    • 14.2.1.2 PUBLIC 389
  • 14.2.2 BY CATEGORY 389
    • 14.2.2.1 TIER 1 390
    • 14.2.2.2 TIER 2 390
    • 14.2.2.3 TIER 3 390
• 14.3 MULTISPECIALTY CLINICS 390
• 14.4 DERMATOLOGY CENTERS 391
• 14.5 MEDICAL SPAS AND BEAUTY CENTERS 392
• 14.6 OTHERS 393

15 ASIA PACIFIC FAT REDUCTION MARKET, BY DISTRIBUTION CHANNEL 395

• 15.1 OVERVIEW 396
• 15.2 DIRECT TENDERS 399
• 15.3 RETAIL SALES 400
• 15.4 THIRD PARTY DISTRIBUTORS 401
• 15.5 OTHERS 402

16 ASIA PACIFIC FAT REDUCTION MARKET, BY REGION 403

• 16.1 ASIA PACIFIC 404
  • 16.1.1 JAPAN 424
  • 16.1.2 INDIA 442
  • 16.1.3 CHINA 459
  • 16.1.4 SOUTH KOREA 477
  • 16.1.5 THAILAND 495
  • 16.1.6 MALAYSIA 512
  • 16.1.7 SINGAPORE 530
  • 16.1.8 AUSTRALIA 548
  • 16.1.9 PHILIPPINES 565
  • 16.1.10 TAIWAN 583
  • 16.1.11 INDONESIA 600
  • 16.1.12 NEW ZEALAND 617
  • 16.1.13 VIETNAM 634
  • 16.1.14 PAKISTAN 648
  • 16.1.15 UZBEKISTAN 665
  • 16.1.16 MYANMAR 682
  • 16.1.17 NEPAL 698
  • 16.1.18 CAMBODIA 714
  • 16.1.19 REST OF ASIA-PACIFIC 731

17 ASIA PACIFIC FAT REDUCTION MARKET, COMPANY LANDSCAPE 732

• 17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 732

18 ASIA PACIFIC FAT REDUCTION MARKET, COMPANY LANDSCAPE COUNTRY WISE 733

• 18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 733
  • 18.1.1 COMPANY SHARE ANALYSIS: JAPAN 733
    • 18.1.1.1 ABBVIE INC. 734
    • 18.1.1.2 CYNOSURE 735
    • 18.1.1.3 CANDELA CORPORATION 736
    • 18.1.1.4 CUTERA 737
    • 18.1.1.5 VENUS CONCEPT 738
  • 18.1.2 COMPANY SHARE ANALYSIS: INDIA 739
    • 18.1.2.1 COMPANY SHARE ANALYSIS: INDIA 739
    • 18.1.2.2 ABBVIE INC. 740
    • 18.1.2.3 ALMA LASERS 741
    • 18.1.2.4 CANDELA CORPORATION 742
  • 18.1.3 COMPANY SHARE ANALYSIS: CHINA 743
    • 18.1.3.1 COMPANY SHARE ANALYSIS: CHINA 743
    • 18.1.3.2 ABBVIE INC. 744
    • 18.1.3.3 CANDELA CORPORATION 745
    • 18.1.3.4 VENUS CONCEPT 746
  • 18.1.4 COMPANY SHARE ANALYSIS: SOUTH KOREA 747
    • 18.1.4.1 COMPANY SHARE ANALYSIS: SOUTH KOREA 747
    • 18.1.4.2 ALMA LASERS 748
    • 18.1.4.3 CANDELA CORPORATION 749
  • 18.1.5 COMPANY SHARE ANALYSIS: SINGAPORE 750
    • 18.1.5.1 COMPANY SHARE ANALYSIS: SINGAPORE 750
    • 18.1.5.2 ABBVIE INC. 751
    • 18.1.5.3 CANDELA CORPORATION 752
  • 18.1.6 COMPANY SHARE ANALYSIS: AUSTRALIA 753
    • 18.1.6.1 COMPANY SHARE ANALYSIS: AUSTRALIA 753
    • 18.1.6.2 ABBVIE INC. 754
    • 18.1.6.3 CYNOSURE 755
    • 18.1.6.4 ALMA LASERS 756
    • 18.1.6.5 CANDELA CORPORATION 757
    • 18.1.6.6 VENUS CONCEPT 758
  • 18.1.7 COMPANY SHARE ANALYSIS: THAILAND 759
    • 18.1.7.1 COMPANY SHARE ANALYSIS: THAILAND 759
    • 18.1.7.2 ABBVIE INC. 760
    • 18.1.7.3 CANDELA CORPORATION 761
  • 18.1.8 COMPANY SHARE ANALYSIS: MALAYSIA 762
    • 18.1.8.1 COMPANY SHARE ANALYSIS: MALAYSIA 762
    • 18.1.8.2 ABBVIE INC. 763
    • 18.1.8.3 CANDELA CORPORATION 764
  • 18.1.9 COMPANY SHARE ANALYSIS: INDONESIA 765
    • 18.1.9.1 COMPANY SHARE ANALYSIS: INDONESIA 765
    • 18.1.9.2 CANDELA CORPORATION 766
    • 18.1.9.3 DEXLEVO AESTHETIC 767
  • 18.1.10 COMPANY SHARE ANALYSIS: VIETNAM 768
    • 18.1.10.1 COMPANY SHARE ANALYSIS: VIETNAM 768
    • 18.1.10.2 CANDELA CORPORATION 769
    • 18.1.10.3 SOLTA MEDICAL (SUBSIDIARY OF BAUSCH & LOMB INCORPORATED) 770
  • 18.1.11 COMPANY SHARE ANALYSIS: CAMBODIA 771
    • 18.1.11.1 COMPANY SHARE ANALYSIS: CAMBODIA 771
    • 18.1.11.2 CANDELA CORPORATION 772
  • 18.1.12 COMPANY SHARE ANALYSIS: PHILIPPINES 773
    • 18.1.12.1 COMPANY SHARE ANALYSIS: PHILIPPINES 773
    • 18.1.12.2 CANDELA CORPORATION 774
  • 18.1.13 COMPANY SHARE ANALYSIS: TAIWAN 775
    • 18.1.13.1 COMPANY SHARE ANALYSIS: TAIWAN 775
    • 18.1.13.2 ABBVIE INC. 776
    • 18.1.13.3 CANDELA CORPORATION 777
  • 18.1.14 COMPANY SHARE ANALYSIS: NEW ZEALAND 778
    • 18.1.14.1 COMPANY SHARE ANALYSIS: NEW ZEALAND 778
    • 18.1.14.2 ABBVIE INC. 779
    • 18.1.14.3 CANDELA CORPORATION 780
  • 18.1.15 COMPANY SHARE ANALYSIS: MYANMAR 781
    • 18.1.15.1 COMPANY SHARE ANALYSIS: MYANMAR 781
    • 18.1.15.2 HIRONIC CO LTD 782
  • 18.1.16 COMPANY SHARE ANALYSIS: PAKISTAN 783
    • 18.1.16.1 COMPANY SHARE ANALYSIS: PAKISTAN 783
    • 18.1.16.2 CANDELA CORPORATION 784
    • 18.1.16.3 HIRONIC CO LTD 785
  • 18.1.17 COMPANY SHARE ANALYSIS: NEPAL 786
    • 18.1.17.1 COMPANY SHARE ANALYSIS: NEPAL 786
    • 18.1.17.2 CANDELA CORPORATION 787
    • 18.1.17.3 HIRONIC CO LTD 788
  • 18.1.18 COMPANY SHARE ANALYSIS: UZBEKISTAN 789
    • 18.1.18.1 COMPANY SHARE ANALYSIS: UZBEKISTAN 789
    • 18.1.18.2 BTL GROUP OF COMPANIES 790

19 SWOT ANALYSIS 791

20 ASIA PACIFIC FAT REDUCTION MARKET, COMPANY PROFILINGS 792

• 20.1 ABBVIE INC.(2022) 792
  • 20.1.1 COMPANY SNAPSHOT 792
  • 20.1.2 REVENUE ANALYSIS 792
  • 20.1.3 COMPANY SHARE ANALYSIS 793
  • 20.1.4 PRODUCT PORTFOLIO 793
  • 20.1.5 RECENT DEVELOPMENTS 794
• 20.2 CYNOSURE 795
  • 20.2.1 COMPANY SNAPSHOT 795
  • 20.2.2 COMPANY SHARE ANALYSIS 795
  • 20.2.3 PRODUCT PORTFOLIO 796
  • 20.2.4 RECENT DEVELOPMENTS 796
• 20.3 ALMA LASERS 797
  • 20.3.1 COMPANY SNAPSHOT 797
  • 20.3.2 COMPANY SHARE ANALYSIS 797
  • 20.3.3 PRODUCT PORTFOLIO 798
  • 20.3.4 RECENT DEVELOPMENT 798
• 20.4 CANDELA CORPORATION 799
  • 20.4.1 COMPANY SNAPSHOT 799
  • 20.4.2 COMPANY SHARE ANALYSIS 799
  • 20.4.3 PRODUCT PORTFOLIO 800
  • 20.4.4 RECENT DEVELOPMENT 800
• 20.5 MERZ NORTH AMERICA, INC. 801
  • 20.5.1 COMPANY SNAPSHOT 801
  • 20.5.2 COMPANY SHARE ANALYSIS 801
  • 20.5.3 PRODUCT PORTFOLIO 802
  • 20.5.4 RECENT DEVELOPMENTS 802
• 20.6 3D AESTHETICS 803
  • 20.6.1 COMPANY SNAPSHOT 803
  • 20.6.2 PRODUCT PORTFOLIO 803
  • 20.6.3 RECENT DEVELOPMENT 803
• 20.7 ADVIN HEALTH CARE 804
  • 20.7.1 COMPANY SNAPSHOT 804
  • 20.7.2 PRODUCT PORTFOLIO 804
  • 20.7.3 RECENT DEVELOPMENT 804
• 20.8 BLACK & BLACK SURGICAL 805
  • 20.8.1 COMPANY SNAPSHOT 805
  • 20.8.2 PRODUCT PORTFOLIO 805
  • 20.8.3 RECENT DEVELOPMENT 805
• 20.9 BTL GROUP OF COMPANIES 806
  • 20.9.1 COMPANY SNAPSHOT 806
  • 20.9.2 PRODUCT PORTFOLIO 806
  • 20.9.3 RECENT DEVELOPMENTS 806
• 20.10 BAUSCH HEALTH COMPANIES INC. 807
  • 20.10.1 COMPANY SNAPSHOT 807
  • 20.10.2 REVENUE ANALYSIS 807
  • 20.10.3 PRODUCT PORTFOLIO 808
  • 20.10.4 RECENT DEVELOPMENT 808
• 20.11 CUTERA (2022) 809
  • 20.11.1 COMPANY SNAPSHOT 809
  • 20.11.2 REVENUE ANALYSIS 809
  • 20.11.3 PRODUCT PORTFOLIO 810
  • 20.11.4 RECENT DEVELOPMENT 810
• 20.12 DEXLEVOAESTHETIC 811
  • 20.12.1 COMPANY SNAPSHOT 811
  • 20.12.2 PRODUCT PORTFOLIO 811
  • 20.12.3 RECENT DEVELOPMENT 811
• 20.13 ERCHONIA CORPORATION 812
  • 20.13.1 COMPANY SNAPSHOT 812
  • 20.13.2 PRODUCT PORTFOLIO 812
  • 20.13.3 RECENT DEVELOPMENT 812
• 20.14 FOTONA 813
  • 20.14.1 COMPANY SNAPSHOT 813
  • 20.14.2 PRODUCT PORTFOLIO 813
  • 20.14.3 RECENT DEVELOPMENT 813
• 20.15 GENESIS BIOSYSTEMS, INC. 814
  • 20.15.1 COMPANY SNAPSHOT 814
  • 20.15.2 PRODUCT PORTFOLIO 814
  • 20.15.3 RECENT DEVELOPMENT 814
• 20.16 HIRONIC CO., LTD. 815
  • 20.16.1 COMPANY SNAPSHOT 815
  • 20.16.2 REVENUE ANALYSIS 815
  • 20.16.3 PRODUCT PORTFOLIO 816
  • 20.16.4 RECENT DEVELOPMENT 816
• 20.17 IMPLANTECH 817
  • 20.17.1 COMPANY SNAPSHOT 817
  • 20.17.2 PRODUCT PORTFOLIO 817
  • 20.17.3 RECENT DEVELOPMENTS 818

• 20.18 INTROPHARMA 819
  • 20.18.1 COMPANY SNAPSHOT 819
  • 20.18.2 PRODUCT PORTFOLIO 819
  • 20.18.3 RECENT DEVELOPMENT 819
• 20.19 LEADERMA INC. 820
  • 20.19.1 COMPANY SNAPSHOT 820
  • 20.19.2 PRODUCT PORTFOLIO 820
  • 20.19.3 RECENT DEVELOPMENT 820
• 20.20 LYNTON LASERS LTD 821
  • 20.20.1 COMPANY SNAPSHOT 821
  • 20.20.2 PRODUCT PORTFOLIO 821
  • 20.20.3 RECENT DEVELOPMENT 821
• 20.21 MENTOR WORLDWIDE LLC (A PART OF JOHNSON & JOHNSON SERVICES, INC.) 822
  • 20.21.1 COMPANY SNAPSHOT 822
  • 20.21.2 REVENUE ANALYSIS 822
  • 20.21.3 PRODUCT PORTFOLIO 823
  • 20.21.4 RECENT DEVELOPMENT 823
• 20.22 MICROAIRE SURGICAL INSTRUMENTS, LLC. 824
  • 20.22.1 COMPANY SNAPSHOT 824
  • 20.22.2 PRODUCT PORTFOLIO 824
  • 20.22.3 RECENT DEVELOPMENT 824
• 20.23 MOLLER MEDICAL 825
  • 20.23.1 COMPANY SNAPSHOT 825
  • 20.23.2 PRODUCT PORTFOLIO 825
  • 20.23.3 RECENT DEVELOPMENT 825
• 20.24 POLLOGEN (A SUBSIDIARY OF LUMENIS BE LTD.) 826
  • 20.24.1 COMPANY SNAPSHOT 826
  • 20.24.2 PRODUCT PORTFOLIO 826
  • 20.24.3 RECENT DEVELOPMENT 826
• 20.25 SILIMED 827
  • 20.25.1 COMPANY SNAPSHOT 827
  • 20.25.2 PRODUCT PORTFOLIO 827
  • 20.25.3 RECENT DEVELOPMENTS 827
• 20.26 SURGIFORM INNOVATIVE SURGICAL PRODUCTS 828
  • 20.26.1 COMPANY SNAPSHOT 828
  • 20.26.2 PRODUCT PORTFOLIO 828
  • 20.26.3 RECENT DEVELOPMENT 828
• 20.27 VENUS CONCEPT 829
  • 20.27.1 COMPANY SNAPSHOT 829
  • 20.27.2 REVENUE ANALYSIS 829
  • 20.27.3 PRODUCT PORTFOLIO 830
  • 20.27.4 RECENT DEVELOPMENT 830

21 QUESTIONNAIRE 831

22 RELATED REPORTS 835

LIST OF FIGURES

• FIGURE 1 ASIA PACIFIC FAT REDUCTION MARKET: SEGMENTATION 78
• FIGURE 2 ASIA PACIFIC FAT REDUCTION MARKET: DATA TRIANGULATION 81
• FIGURE 3 ASIA PACIFIC FAT REDUCTION MARKET: DROC ANALYSIS 82
• FIGURE 4 ASIA PACIFIC FAT REDUCTION MARKET: ASIA PACIFIC VS. REGIONAL MARKET ANALYSIS 83
• FIGURE 5 ASIA PACIFIC FAT REDUCTION MARKET: COMPANY RESEARCH ANALYSIS 83
• FIGURE 6 ASIA PACIFIC FAT REDUCTION MARKET: INTERVIEW DEMOGRAPHICS 84
• FIGURE 7 ASIA PACIFIC FAT REDUCTION MARKET: MULTIVARIATE MODELLING 85
• FIGURE 8 ASIA PACIFIC FAT REDUCTION MARKET: DBMR MARKET POSITION GRID 86
• FIGURE 9 ASIA PACIFIC FAT REDUCTION MARKET: VENDOR SHARE ANALYSIS 87
• FIGURE 10 ASIA PACIFIC FAT REDUCTION MARKET: MARKET APPLICATION COVERAGE GRID 88
• FIGURE 11 ASIA PACIFIC FAT REDUCTION MARKET: SEGMENTATION 92
• FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC FAT REDUCTION MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2023 TO 2033 93
• FIGURE 13 INCREASING DEMAND FOR NON-INVASIVE AND MINIMALLY INVASIVE AESTHETIC PROCEDURES IS EXPECTED TO DRIVE THE ASIA PACIFIC FAT REDUCTION MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2033 94
• FIGURE 14 THE SURGICAL FAT REDUCTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC FAT REDUCTION MARKET IN 2023 & 2033 94
• FIGURE 15 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR THE FAT REDUCTION MANUFACTURERS IN THE FORECAST PERIOD FROM 2023 TO 2033 95
• FIGURE 16 GMP COMPLIANCE FLOW CHART OF DRUG REVIEW PROCESS FOR CAMBODIA 160
• FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC FAT REDUCTION MARKET 174
• FIGURE 18 ASIA PACIFIC FAT REDUCTION MARKET: BY TYPE, 2022 189
• FIGURE 19 ASIA PACIFIC FAT REDUCTION MARKET: BY TYPE, 2023-2033 (USD MILLION) 190
• FIGURE 20 ASIA PACIFIC FAT REDUCTION MARKET: BY TYPE, CAGR (2023-2033) 190
• FIGURE 21 ASIA PACIFIC FAT REDUCTION MARKET: BY TYPE, LIFELINE CURVE 191
• FIGURE 22 ASIA PACIFIC FAT REDUCTION MARKET: BY APPLICATION, 2022 219
• FIGURE 23 ASIA PACIFIC FAT REDUCTION MARKET: BY APPLICATION, 2023-2033 (USD MILLION) 220
• FIGURE 24 ASIA PACIFIC FAT REDUCTION MARKET: BY APPLICATION, CAGR (2023-2033) 220
• FIGURE 25 ASIA PACIFIC FAT REDUCTION MARKET: BY APPLICATION, LIFELINE CURVE 221
• FIGURE 26 ASIA PACIFIC FAT REDUCTION MARKET: BY GENDER, 2022 230
• FIGURE 27 ASIA PACIFIC FAT REDUCTION MARKET: BY GENDER, 2023-2033 (USD MILLION) 231
• FIGURE 28 ASIA PACIFIC FAT REDUCTION MARKET: BY GENDER, CAGR (2023-2033) 231
• FIGURE 29 ASIA PACIFIC FAT REDUCTION MARKET: BY GENDER, LIFELINE CURVE 232
• FIGURE 30 ASIA PACIFIC FAT REDUCTION MARKET: BY AGE GROUP, 2022 236
• FIGURE 31 ASIA PACIFIC FAT REDUCTION MARKET: BY AGE GROUP, 2023-2033 (USD MILLION) 237
• FIGURE 32 ASIA PACIFIC FAT REDUCTION MARKET: BY AGE GROUP, CAGR (2023-2033) 237
• FIGURE 33 ASIA PACIFIC FAT REDUCTION MARKET: BY AGE GROUP, LIFELINE CURVE 238
• FIGURE 34 ASIA PACIFIC FAT REDUCTION MARKET: BY END USER, 2022 244
• FIGURE 35 ASIA PACIFIC FAT REDUCTION MARKET: BY END USER, 2023-2033 (USD MILLION) 245
• FIGURE 36 ASIA PACIFIC FAT REDUCTION MARKET: BY END USER, CAGR (2023-2033) 245
• FIGURE 37 ASIA PACIFIC FAT REDUCTION MARKET: BY END USER, LIFELINE CURVE 246
• FIGURE 38 ASIA PACIFIC FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2022 255
• FIGURE 39 ASIA PACIFIC FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2023-2033 (USD MILLION) 256
• FIGURE 40 ASIA PACIFIC FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2033) 256
• FIGURE 41 ASIA PACIFIC FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 257
• FIGURE 42 ASIA-PACIFIC FAT REDUCTION MARKET: SNAPSHOT (2022) 264
• FIGURE 43 ASIA-PACIFIC FAT REDUCTION MARKET: BY COUNTRY (2022) 265
• FIGURE 44 ASIA-PACIFIC FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 265
• FIGURE 45 ASIA-PACIFIC FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 266
• FIGURE 46 ASIA-PACIFIC FAT REDUCTION MARKET: BY TYPE (2023-2033) 266
• FIGURE 47 ASIA PACIFIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 591
• FIGURE 48 JAPAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 592
• FIGURE 49 ABBVIE INC.IN JAPAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 593
• FIGURE 50 CYNOSURE IN JAPAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 594
• FIGURE 51 CANDELA CORPORATION IN JAPAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 595
• FIGURE 52 CUTERA IN JAPAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 596
• FIGURE 53 VENUS CONCEPT IN JAPAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 597
• FIGURE 54 THE INDIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 598
• FIGURE 55 ABBVIE INC.IN INDIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 599
• FIGURE 56 ALMA LASERS IN INDIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 600
• FIGURE 57 CANDELA CORPORATION IN INDIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 601
• FIGURE 58 THE CHINA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 602
• FIGURE 59 ABBVIE INC.IN CHINA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 603
• FIGURE 60 CANDELA CORPORATION IN CHINA. IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 604
• FIGURE 61 VENUS CONCEPT IN CHINA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 605
• FIGURE 62 THE SOUTH KOREA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 606
• FIGURE 63 ALMA LASERS . IN SOUTH KOREA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 607
• FIGURE 64 CANDELA CORPORATION IN SOUTH KOREA IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 608
• FIGURE 65 THE SINGAPORE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 609
• FIGURE 66 ABBVIE INC.IN SINGAPORE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 610
• FIGURE 67 CANDELA CORPORATION IN SINGAPORE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 611
• FIGURE 68 THE AUSTRALIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 612
• FIGURE 69 ABBVIE INC.IN AUSTRALIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 613
• FIGURE 70 CYNOSURE IN AUSTRALIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 614
• FIGURE 71 ALMA LASERS IN AUSTRALIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 615
• FIGURE 72 CANDELA CORPORATION IN AUSTRALIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 616
• FIGURE 73 VENUS CONCEPT IN AUSTRALIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 617
• FIGURE 74 THE THAILAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 618
• FIGURE 75 ABBVIE INC.IN THAILAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 619
• FIGURE 76 CANDELA CORPORATION IN THAILAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 620
• FIGURE 77 THE MALAYSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 621
• FIGURE 78 ABBVIE INC.IN MALAYSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 622
• FIGURE 79 CANDELA CORPORATION IN MALAYSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 623
• FIGURE 80 THE INDONESIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 624
• FIGURE 81 CANDELA CORPORATION IN INDONESIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 625
• FIGURE 82 DEXLEVO AESTHETIC IN INDONESIA IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 626
• FIGURE 83 THE VIETNAM FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 627
• FIGURE 84 CANDELA CORPORATION IN VIETNAM FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 628
• FIGURE 85 SOLTA MEDICAL (SUBSIDIARY OF BAUSCH & LOMB INCORPORATED) IN VIETNAM FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 629
• FIGURE 86 CAMBODIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 630
• FIGURE 87 CANDELA CORPORATION IN CAMBODIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 631
• FIGURE 88 PHILIPPINES FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 632
• FIGURE 89 CANDELA CORPORATION IN PHILIPPINES FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 633
• FIGURE 90 TAIWAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 634
• FIGURE 91 ABBVIE INC.IN TAIWAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 635
• FIGURE 92 CANDELA CORPORATION IN TAIWAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 636
• FIGURE 93 NEW ZEALAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 637
• FIGURE 94 ABBVIE INC.IN NEW ZEALAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 638
• FIGURE 95 CANDELA CORPORATION IN NEW ZEALAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 639
• FIGURE 96 MYANMAR FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 640
• FIGURE 97 HIRONIC CO LTD IN MYANMAR FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 641
• FIGURE 98 PAKISTAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 642
• FIGURE 99 CANDELA CORPORATION IN PAKISTAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 643
• FIGURE 100 HIRONIC CO LTD IN MYANMAR FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 644
• FIGURE 101 NEPAL FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 645
• FIGURE 102 CANDELA CORPORATION IN NEPAL FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 646
• FIGURE 103 HIRONIC CO LTD IN NEPAL FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 647
• FIGURE 104 UZBEKISTAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 648
• FIGURE 105 BTL GROUP OF COMPANIES IN UZBEKISTAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 649